Medical Syringe Production: ISO 13485 Cleanroom Requirements and 0.01 mm Repeatability on All-Electric Machines

Why medical syringe molding sits in a different compliance universe

If you walk a syringe production hall next to an automotive bumper hall, the machines look the same. The regulatory envelope is not. A syringe barrel is a primary packaging component for a sterile drug product, which puts it directly under ISO 13485:2016 and — depending on the destination market — under EU MDR 2017/745, FDA 21 CFR Part 820, or both.

Three structural consequences follow:

• Design controls apply to the machine itself, not just to the syringe. ISO 13485 clause 7.3 requires design and development planning for any product the organization has not previously produced in that configuration. A new machine on a new cell is a design change, and the documentation has to travel with it.
• Process validation is mandatory, not optional. An IQ/OQ/PQ stack is the auditor's first stop, and the PQ needs Cpk data on critical dimensions — not just a pass/fail on first article.
• Supply-chain traceability runs down to the polymer lot. Under EU MDR 2017/745, an OEM's technical file must reference the supplier's quality system; under FDA 21 CFR 820.50, purchasing controls must include supplier evaluation. Both expect a documented chain from resin supplier to finished syringe.

The practical impact is that an injection molding machine quote is no longer a price-and-tonnage conversation. It is a documentation conversation that happens to end in a tonnage decision.

ISO 13485 cleanroom classification: translating Class 7 to machine-floor decisions

ISO 13485:2016 itself does not assign a cleanroom class. It points to ISO 14644-1, which is where the particle concentration limits live. The BSI's published summary of the standard confirms that cleanroom control is expected for sterile medical device manufacture and that the chosen class must be justified by a risk-based assessment of the product. The most common production envelope for syringe barrel molding, in practice, looks like this:

• ISO Class 8 at rest around the molding cell when the line is idle.
• ISO Class 7 in operation during steady-state molding — typically corresponding to about 352,000 particles of 0.5 µm or larger per cubic meter of air.
• ISO Class 5 around the open mold during transfer, when the mold opens and the parts are exposed.

This is what an auditor will check against your HVAC layout. Specifically, they will look for:

• A documented air change rate per hour for each zone (typically 20 to 40 air changes per hour for Class 7).
• Pressure cascade from the most critical zone outward, with a measurable differential (commonly 10 to 15 Pa between adjacent zones).
• Particle counter mapping at rest and in operation, with the locations justified by a risk assessment.
• Operator gowning procedure that maintains the documented class.

The machine you place inside this envelope has to be cleanroom-friendly in a way that an automotive machine does not. Three specifics matter: hydraulic fluid leaks must be designed out of the part-touching zone (electric axes solve this directly); the machine frame should be designed for washdown (the SUCCESSOR SK series uses self-lubricating copper bushings on guide surfaces for this reason); and the controller must be sealed to IP54 or better so that HVAC downwash does not carry dust into the cabinet.

Why 0.01 mm repeatability on all-electric (or hybrid) machines matters for syringe dimensions

The 0.01 mm number comes up in nearly every medical molding conversation. Here is the engineering reality behind it.

A 1 mL syringe barrel molded in polypropylene has, on a typical print:

• Barrel wall thickness in the 0.8 to 1.2 mm range, with a tolerance of ±0.05 mm on most prints.
• Luer slip or Luer lock taper held to about ±0.05 mm on the critical engagement dimensions, because the male Luer taper on the syringe has to mate with the female taper on the needle hub or the cap.
• Plunger seal ridge dimensions in the 0.02 to 0.05 mm tolerance band, where excessive flash forces a manual rework step or scrap.

Stack those tolerances against the molding process window, and you get a useful back-of-envelope test. If your injection position repeatability drifts by ±0.05 mm shot to shot, you have already eaten half your Luer taper tolerance. If you hold ±0.01 mm shot to shot, you have left yourself room to live with normal melt viscosity variation.

Modern servo-electric injection axes with linear position encoders and closed-loop pressure feedback can hold 0.01 mm position repeatability in production — but only as a system result, not as a controller number on a nameplate. Three things sit underneath that number:

• Screw and barrel wear. As clearance grows between screw and barrel, shot weight drifts, and shot weight drift forces the controller to chase position. A worn screw will silently destroy your Cpk.
• Mold thermal stability. PID barrel temperature control on the SK series holds deviation in the single-digit degrees Celsius; mold-side thermostats must do the same on the water/oil circuits.
• An active process capability program. Cpk measured monthly, on critical features, written down, and acted on when it trends below 1.33. Without this, 0.01 mm is wishful.

This is why the conversation at the machine builder's FAT should include a written statement of position repeatability measured against a defined test mold, not a brochure number.

The hybrid machine counter-argument: where all-hydraulic still wins for syringe production

A common reflex in medical molding is to ask only for "all-electric" machines, on the assumption that electric equals clean. That is partially correct and partially misleading, and the engineer in the room should know which is which.

A hybrid machine uses an electric servo motor for injection, plasticizing, and pressure regulation, while retaining a hydraulic circuit for clamping force. From the part's perspective, every dimension-defining axis is electrically driven; the hydraulic circuit holds the mold closed but does not contact the melt, the cavity surface, or the part. This is the architecture used in SUCCESSOR's hybrid platform, where the servo pump control on injection and a closed-loop process controller deliver ±0.5% pressure stability on the holding phase.

The honest counter-argument for hydraulic clamping on a medical cell is:

• Clamping force stability under peak injection pressure. A 1700 kN clamp with a 2320 Bar injection pressure on a 42 mm screw, like the SK-170 A-configuration, has to hold platen parallelism through peak cavity pressure. Hydraulic clamping with a wide tie-bar spacing handles this with margin; some toggle clamps do not.
• Long-term clamp force repeatability. A hydraulic clamp with a pressure transducer and closed-loop valve does not drift over years the way a toggle mechanism can.
• Contamination control. Modern food-grade hydraulic fluids and sealed glands keep the cell cleaner than the older hydraulic machines the "all-electric only" rule was originally written to exclude.

The summary rule of thumb I give to new medical customers: electric drives for every axis that defines the part, hydraulic or electric for the clamp, and a documented fluid program that an auditor can read.

Five machine-side decisions an ISO 13485 auditor will look for first

When an ISO 13485 auditor walks a medical molding cell, they typically reach for the same five documents first. None of them are exotic, and all of them can be written around a properly specified machine.

1. IQ (Installation Qualification) protocol, including the machine CE declaration, utility mapping (compressed air, cooling water, power, HVAC interface), and cleanroom interface points.
2. OQ (Operational Qualification) report, covering the documented operating window — minimum and maximum shot weight, temperature limits, clamp force range, and cycle time envelope.
3. PQ (Performance Qualification) with Cpk data on the critical syringe dimensions, run on three consecutive lots, with the data retained for the post-market surveillance file.
4. Process FMEA with severity, occurrence, and detection scores for each failure mode, linked back to the control plan. The auditor will trace a high-severity failure mode to a control and then to a record.
5. Calibration records for the position transducers, pressure transducers, and temperature sensors, with traceability to national standards. On the SK series, the linear encoder on the injection axis and the closed-loop pressure transducer are the calibration anchors.

The reason to enumerate these is that the machine builder's job ends at IQ/OQ support; the PQ is the producer's document. The handover meeting at FAT is the right place to lock down which side of the line owns which document.

Specifying a SK-series machine for medical production: a 5-parameter checklist

For a syringe producer evaluating a SK-series servo-electric platform from SUCCESSOR, five parameters determine the right model. The table below summarizes the SK-110 and SK-170 reference configurations from the published product page; both are realistic candidates for syringe barrel and plunger cells respectively.

The mapping to a syringe line is straightforward:

• Barrel cell: SK-170 to SK-220, configured with the smallest screw diameter for thin-wall barrel work, paired with a hybrid injection molding machine platform when the cell needs to share molds with existing hydraulic clamp infrastructure.
• Plunger cell: SK-110 to SK-140, configured for tighter shot weight control, with the machine fully enclosed for ISO Class 7 operation.
• Luer connector cell (if produced in-house): SK-140 to SK-170, with a medical grade servo options package and EUROMAP 67 robot interface for automated transfer into the Class 5 zone.

From quotation to validation: the realistic 12-week timeline

The honest answer to "how long until my line is validated" is twelve to sixteen weeks, and the engineer who promises less has not done it. The week-by-week layout below reflects the actual SK-series FAT and on-site validation cycle we run for medical customers.

• Weeks 1–2: Quotation, application engineering review, mold-machine interface drawing, and cleanroom interface review. This is where the IQ scope is drafted and agreed.
• Weeks 3–6: Factory acceptance testing (FAT) at the SUCCESSOR plant in Ningbo. The customer typically attends for two to three days; the OQ is run here, and the FAT protocol covers position, pressure, and temperature windows.
• Weeks 7–10: Shipping, installation, and utility hookup at the customer's site. The cleanroom interface (compressed air, chilled water, HVAC exhaust, particle counter tie-in) is completed in this window.
• Weeks 11–13: On-site IQ/OQ execution. PQ begins at the end of this window with the customer's first production mold.
• Weeks 14–16: PQ closure, Cpk reporting, and process FMEA sign-off. The line is released to commercial medical use at the end of this window.

The single most common reason the timeline slips is a mismatch between the cleanroom interface drawing at quotation and the actual HVAC capacity at the site. Locking that drawing at week 2, not week 10, is the cheapest fix available.

If you are evaluating a SK-series or hybrid platform for a medical production cell, the practical next step is to request medical molding consultation with our engineering team. The first conversation is a 30-minute review of your product, your cleanroom envelope, and your destination market — and it produces a written feasibility summary, not a quote.

Frequently Asked Questions